RE: Short vs Long ...24 Jan 2023 12:26
I agree and don't think February 21st will mean Polygon coming in with some low ball offer. But the fact an entire year will have passed by with no materially good news or clear path forward for the company would not look good at all.
That said, I am still confident, hopeful that common sense will prevail and SNG001 will be given the opportunity to prove itself one more time. Common sense because Covid (and respiratory viruses in general) is still a potentially big threat moving forward and surely the likes of the NIH/NIHR will not take their eyes off the ball and make sure therapeutics continue to be developed. Because let's face it, their ain't much in the cupboard to use right now! Common sense because SNG001 did have excellent P2 results, missed out on P3 because of poor trial design, not being powered enough and yes, maybe poorly managed from Synairgen's point of view. Common sense because we did pass ACTIV-2 P2, which not many did and unlike the NIH did with SAB, they haven't formally at least dropped us like a hot potato.
I could go on, but I do acknowledge MrCosts point that the comms isn't great. Even if they can't tell us anything, be visible, give us a few smiles. And as utterly mental AB4 is, we do have one drug and everything is riding on it. So yes, massive risk, albeit we have suffered big losses already so if it goes to £0 would it really be anywhere near as painful as Feb 2021? But that's also why there is potentially massive upside. It's called risk vs reward.